Gsa Capital Partners LLP Chimerix Inc Transaction History

Gsa Capital Partners LLP

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$1.1 - $1.54 $2,807 - $3,930	-2,552 Reduced 13.46%	16,411 $19,000
Q1 2023 May 12, 2023	SELL	$1.19 - $2.09 $1,220 - $2,144	-1,026 Reduced 5.13%	18,963 $23,000
Q4 2022 Feb 13, 2023	SELL	$1.67 - $2.35 $529,713 - $745,405	-317,194 Reduced 94.07%	19,989 $37,000
Q3 2022 Nov 14, 2022	SELL	$1.81 - $2.76 $31,550 - $48,109	-17,431 Reduced 4.92%	337,183 $651,000
Q2 2022 Aug 09, 2022	BUY	$1.34 - $5.34 $354,874 - $1.41 Million	264,832 Added 294.97%	354,614 $738,000
Q1 2022 May 11, 2022	SELL	$4.58 - $6.8 $65,191 - $96,791	-14,234 Reduced 13.68%	89,782 $411,000
Q4 2021 Feb 14, 2022	SELL	$5.23 - $7.18 $489,930 - $672,600	-93,677 Reduced 47.39%	104,016 $669,000
Q3 2021 Nov 12, 2021	BUY	$5.94 - $8.75 $906,129 - $1.33 Million	152,547 Added 337.9%	197,693 $1.22 Million
Q2 2021 Aug 05, 2021	SELL	$7.54 - $9.79 $20,923 - $27,167	-2,775 Reduced 5.79%	45,146 $361,000
Q1 2021 May 10, 2021	SELL	$4.76 - $11.25 $375,973 - $888,592	-78,986 Reduced 62.24%	47,921 $462,000
Q4 2020 Feb 03, 2021	SELL	$2.43 - $5.42 $26,103 - $58,221	-10,742 Reduced 7.8%	126,907 $613,000
Q3 2020 Nov 06, 2020	BUY	$2.3 - $3.72 $316,592 - $512,054	137,649 New	137,649 $343,000
Q2 2020 Aug 11, 2020	SELL	$1.33 - $3.63 $42,903 - $117,096	-32,258 Closed	0 $0
Q1 2020 May 12, 2020	BUY	$1.27 - $2.33 $40,967 - $75,161	32,258 New	32,258 $46,000
Q4 2017 Feb 14, 2018	SELL	$4.32 - $5.52 $216,289 - $276,369	-50,067 Closed	0 $0
Q3 2017 Nov 20, 2017	BUY	$4.35 - $5.25 $217,791 - $262,851	50,067	50,067 $263,000

36.8M

72.2K

169K

Ticker CMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,622,896
Market Cap $85M
Description
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.